background figure 1 background figure 2


Jan, 27, 2023

Regel Therapeutics launches its website and welcomes Andrew Schiermeier to its Board of Directors.

CAMBRIDGE, Mass, and BERKELEY, Calif, January 27th 2023 / PRNewswire -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, is pleased to announce the launch of its website, the addition of Andrew Schiermeier, Ph.D to its Board of Directors and the establishment of its Scientific Advisory Board.